tiprankstipranks
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
US Market
ARWR
Arrowhead Pharmaceuticals
RESEARCH TOOLSreports

Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

1,666 Followers
See the Price Targets and Ratings of:

ARWR Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
7 Buy
3 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Arrowhead
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARWR Stock 12 Month Forecast

Average Price Target

$89.38
▲(46.45% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $89.38 with a high forecast of $110.00 and a low forecast of $78.00. The average price target represents a 46.45% change from the last price of $61.03.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","36":"$36","61":"$61","86":"$86","111":"$111"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$89.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$78.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,36,61,86,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.33,67.84307692307692,71.35615384615384,74.86923076923077,78.38230769230769,81.89538461538461,85.40846153846154,88.92153846153846,92.43461538461538,95.94769230769231,99.46076923076923,102.97384615384615,106.48692307692308,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.33,66.25692307692307,68.18384615384615,70.11076923076922,72.03769230769231,73.96461538461539,75.89153846153846,77.81846153846153,79.74538461538461,81.6723076923077,83.59923076923076,85.52615384615385,87.45307692307692,{"y":89.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.33,65.38153846153845,66.43307692307692,67.48461538461538,68.53615384615385,69.58769230769231,70.63923076923076,71.69076923076923,72.74230769230769,73.79384615384615,74.84538461538462,75.89692307692307,76.94846153846154,{"y":78,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.205,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.09,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.68,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.33,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$110.00Average Price Target$89.38Lowest Price Target$78.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on ARWR
Jason Gerberry
Bank of America Securities
Bank of America Securities
$84→$81
Buy
32.72%
Upside
Reiterated
03/26/26
Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
Leerink Partners Analyst forecast on ARWR
Mani Foroohar
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
03/26/26
Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (NASDAQ: MAZE), Azitra Inc (NYSE MKT: AZTR) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)
H.C. Wainwright Analyst forecast on ARWR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$100
Buy
63.85%
Upside
Reiterated
03/25/26
Analysts Conflicted on These Healthcare Names: Cibus (NASDAQ: CBUS), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Tarsus Pharmaceuticals (NASDAQ: TARS)
Morgan Stanley Analyst forecast on ARWR
Michael Ulz
Morgan Stanley
Morgan Stanley
$78
Hold
27.81%
Upside
Reiterated
02/17/26
Analysts Conflicted on These Healthcare Names: Idexx Laboratories (NASDAQ: IDXX), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Disc Medicine (NASDAQ: IRON)
Piper Sandler Analyst forecast on ARWR
Edward Tenthoff
Piper Sandler
Piper Sandler
$110
Buy
80.24%
Upside
Reiterated
02/06/26
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Illumina (NASDAQ: ILMN) and Rigel (NASDAQ: RIGL)
TD Cowen Analyst forecast on ARWR
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/05/26
Arrowhead: Early Redemplo Launch Momentum and De-Risked sHTG Pivotal Program Underpin Attractive Buy Thesis
RBC Capital Analyst forecast on ARWR
Luca Issi
RBC Capital
RBC Capital
$80
Buy
31.08%
Upside
Reiterated
02/05/26
Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Envista Holdings (NVST)
B. Riley Securities Analyst forecast on ARWR
Madison Elsaadi
B. Riley Securities
B. Riley Securities
$61→$101
Buy
65.49%
Upside
Reiterated
01/22/26
Arrowhead price target raised to $101 from $61 at B. RileyArrowhead price target raised to $101 from $61 at B. Riley
Chardan Capital Analyst forecast on ARWR
Keay Nakae
Chardan Capital
Chardan Capital
$60→$80
Buy
31.08%
Upside
Reiterated
01/07/26
Arrowhead price target raised to $80 from $60 at ChardanArrowhead price target raised to $80 from $60 at Chardan
Goldman Sachs Analyst forecast on ARWR
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$50→$85
Hold
39.28%
Upside
Reiterated
01/07/26
Arrowhead Pharmaceuticals (ARWR) Gets a Hold from Goldman Sachs
Bernstein Analyst forecast on ARWR
William Pickering
Bernstein
Bernstein
$35
Hold
-42.65%
Downside
Reiterated
12/31/25
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Evolus (NASDAQ: EOLS)
Jefferies Analyst forecast on ARWR
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$67
Buy
9.78%
Upside
Reiterated
12/05/25
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Jefferies
Citi Analyst forecast on ARWR
David Lebowitz
Citi
Citi
$27.8→$17
Hold
-72.14%
Downside
Reiterated
09/03/25
Hold Rating on Arrowhead Pharmaceuticals Amid Strategic Partnership and Market Competition
Barclays Analyst forecast on ARWR
Eliana Merle
Barclays
Barclays
$63→$12
Hold
-80.34%
Downside
Downgraded
07/21/25
UBS downgrades Arrowhead Pharmaceuticals (ARWR) to a Hold
Cantor Fitzgerald Analyst forecast on ARWR
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
05/13/25
Cantor Fitzgerald reiterates Overweight Rating on Arrowhead Pharma (ARWR)Cantor Fitzgerald analyst Elemer Piros reiterated an Overweight rating on Arrowhead Pharma (NASDAQ: ARWR).
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on ARWR
Jason Gerberry
Bank of America Securities
Bank of America Securities
$84→$81
Buy
32.72%
Upside
Reiterated
03/26/26
Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
Leerink Partners Analyst forecast on ARWR
Mani Foroohar
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
03/26/26
Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (NASDAQ: MAZE), Azitra Inc (NYSE MKT: AZTR) and Arrowhead Pharmaceuticals (NASDAQ: ARWR)
H.C. Wainwright Analyst forecast on ARWR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$100
Buy
63.85%
Upside
Reiterated
03/25/26
Analysts Conflicted on These Healthcare Names: Cibus (NASDAQ: CBUS), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Tarsus Pharmaceuticals (NASDAQ: TARS)
Morgan Stanley Analyst forecast on ARWR
Michael Ulz
Morgan Stanley
Morgan Stanley
$78
Hold
27.81%
Upside
Reiterated
02/17/26
Analysts Conflicted on These Healthcare Names: Idexx Laboratories (NASDAQ: IDXX), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Disc Medicine (NASDAQ: IRON)
Piper Sandler Analyst forecast on ARWR
Edward Tenthoff
Piper Sandler
Piper Sandler
$110
Buy
80.24%
Upside
Reiterated
02/06/26
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Illumina (NASDAQ: ILMN) and Rigel (NASDAQ: RIGL)
TD Cowen Analyst forecast on ARWR
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/05/26
Arrowhead: Early Redemplo Launch Momentum and De-Risked sHTG Pivotal Program Underpin Attractive Buy Thesis
RBC Capital Analyst forecast on ARWR
Luca Issi
RBC Capital
RBC Capital
$80
Buy
31.08%
Upside
Reiterated
02/05/26
Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Envista Holdings (NVST)
B. Riley Securities Analyst forecast on ARWR
Madison Elsaadi
B. Riley Securities
B. Riley Securities
$61→$101
Buy
65.49%
Upside
Reiterated
01/22/26
Arrowhead price target raised to $101 from $61 at B. RileyArrowhead price target raised to $101 from $61 at B. Riley
Chardan Capital Analyst forecast on ARWR
Keay Nakae
Chardan Capital
Chardan Capital
$60→$80
Buy
31.08%
Upside
Reiterated
01/07/26
Arrowhead price target raised to $80 from $60 at ChardanArrowhead price target raised to $80 from $60 at Chardan
Goldman Sachs Analyst forecast on ARWR
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$50→$85
Hold
39.28%
Upside
Reiterated
01/07/26
Arrowhead Pharmaceuticals (ARWR) Gets a Hold from Goldman Sachs
Bernstein Analyst forecast on ARWR
William Pickering
Bernstein
Bernstein
$35
Hold
-42.65%
Downside
Reiterated
12/31/25
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Evolus (NASDAQ: EOLS)
Jefferies Analyst forecast on ARWR
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$67
Buy
9.78%
Upside
Reiterated
12/05/25
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Jefferies
Citi Analyst forecast on ARWR
David Lebowitz
Citi
Citi
$27.8→$17
Hold
-72.14%
Downside
Reiterated
09/03/25
Hold Rating on Arrowhead Pharmaceuticals Amid Strategic Partnership and Market Competition
Barclays Analyst forecast on ARWR
Eliana Merle
Barclays
Barclays
$63→$12
Hold
-80.34%
Downside
Downgraded
07/21/25
UBS downgrades Arrowhead Pharmaceuticals (ARWR) to a Hold
Cantor Fitzgerald Analyst forecast on ARWR
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
05/13/25
Cantor Fitzgerald reiterates Overweight Rating on Arrowhead Pharma (ARWR)Cantor Fitzgerald analyst Elemer Piros reiterated an Overweight rating on Arrowhead Pharma (NASDAQ: ARWR).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arrowhead Pharmaceuticals

3 Months
xxx
Success Rate
15/24 ratings generated profit
63%
Average Return
+26.70%
reiterated a xxx
 rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +26.70% per trade.
1 Year
Patrick TrucchioH.C. Wainwright
Success Rate
14/24 ratings generated profit
58%
Average Return
+84.52%
reiterated a buy rating 12 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +84.52% per trade.
2 Years
xxx
Success Rate
21/24 ratings generated profit
88%
Average Return
+134.68%
reiterated a xxx
 rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +134.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARWR Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
6
5
4
5
5
Buy
13
15
23
28
31
Hold
24
17
15
21
28
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
43
37
42
54
64
In the current month, ARWR has received 36 Buy Ratings, 28 Hold Ratings, and 0 Sell Ratings. ARWR average Analyst price target in the past 3 months is 89.38.
Each month's total comprises the sum of three months' worth of ratings.

ARWR Financial Forecast

ARWR Earnings Forecast

Next quarter’s earnings estimate for ARWR is -$1.04 with a range of -$1.52 to $0.34. The previous quarter’s EPS was $0.22. ARWR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ARWR has Performed in-line its overall industry.
Next quarter’s earnings estimate for ARWR is -$1.04 with a range of -$1.52 to $0.34. The previous quarter’s EPS was $0.22. ARWR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ARWR has Performed in-line its overall industry.

ARWR Sales Forecast

Next quarter’s sales forecast for ARWR is $71.50M with a range of $8.50M to $213.00M. The previous quarter’s sales results were $264.03M. ARWR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ARWR has Performed in-line its overall industry.
Next quarter’s sales forecast for ARWR is $71.50M with a range of $8.50M to $213.00M. The previous quarter’s sales results were $264.03M. ARWR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ARWR has Performed in-line its overall industry.

ARWR Stock Forecast FAQ

What is ARWR’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is 89.38.
    What is ARWR’s upside potential, based on the analysts’ average price target?
    Arrowhead Pharmaceuticals has 46.45% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARWR a Buy, Sell or Hold?
          Arrowhead Pharmaceuticals has a consensus rating of Moderate Buy which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Arrowhead Pharmaceuticals’s price target?
            The average price target for Arrowhead Pharmaceuticals is 89.38. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $110.00 ,the lowest forecast is $78.00. The average price target represents 46.45% Increase from the current price of $61.03.
              What do analysts say about Arrowhead Pharmaceuticals?
              Arrowhead Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of ARWR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.